Canada’s Amended Post-Market Surveillance for Medical Devices

by | Jan 21, 2021 | AI, Health Canada, Healthcare, Medical Devices, Post-Market, Quality

Health Canada recently published SOR/2020-262 amending the Food and Drug Regulations and the Medical Devices Regulations (CMDR). The amendments under these regulations strengthen Health Canada’s ability to collect post-market safety information in support of Vanessa’s Law (Protecting Canadians from Unsafe Drugs Act) by providing the authorities with more power to regulate medical devices.1

Currently, product license holders under Health Canada are not required to provide detailed post-market reports, which sometimes leads to a delayed evaluation of medical devices. However, under this amendment, if Health Canada has any reasons to believe that the product poses a serious risk to public health, the license holder may be ordered to submit all the information which is in their possession. The authorities may also disclose confidential business information without notifying the license holder if such disclosure will protect public health.1

Similar to the EU MDR, Health Canada is also beginning to implement the submission of ‘Summary Reports’. Product license holders will be required to submit summary reports on a biennial basis for class II devices and an annual basis for class III and class IV medical devices. When the proposed rule first came out, industry stakeholders expressed concerns about the additional burden on class II device license holders to submit summary reports annually, and thus the requirement for class II devices was reduced from annual report submissions to biennial reports.1 These summary reports include the adverse effects, serious risks of injury to human health that are relevant to the safety of the medical device, and a critical analysis of the information presented in the report.1

The amendment also clarifies that foreign risk notifications must be provided to Health Canada for class II, III, or IV medical devices within the stipulated 72-hour timeline only, thus declining the industry’s request for a 10-day timeline to provide such notifications.1 With this step, Health Canada is trying to incorporate some of the European requirements into its regulations and it will be interesting to see how the industry digests and implements these new requirements.

EMMA International is here to help you with all your regulatory needs. Call us today at +1 248-987-4497 or email us at to know more.

1Health Canada (Dec 2020) Regulations Amending the Food and Drug Regulations and the Medical Devices Regulations (Post-market Surveillance of Medical Devices): SOR/2020-262 retrieved on 1/18/2021 from


Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

Ready to learn more about working with us?

Pin It on Pinterest

Share This